Cardinal Health Raises FY2026 EPS Outlook to $10.00 Amid Strong Growth
Cardinal Health's stock rose 4.61% during regular trading, reaching a 20-day high.
The company has raised its fiscal year 2026 non-GAAP diluted EPS outlook to at least $10.00, up from the previous range of $9.65 to $9.85, reflecting strong performance across its five operating segments. This upgrade is driven by robust demand in specialty distribution, with projected specialty revenues exceeding $50 billion, representing a 16% CAGR. Additionally, Cardinal Health successfully navigated changes related to the Medicare Drug Price Negotiation Program, ensuring its critical role in pharmaceutical distribution.
This positive outlook is expected to attract further investor interest, especially with the upcoming presentation at the J.P. Morgan Healthcare Conference, where the company will showcase its strategic growth initiatives.
Trade with 70% Backtested Accuracy
Analyst Views on CAH
About CAH
About the author

- Impact of Subsidy Changes: As the Trump administration's healthcare policies evolve, particularly with the expiration of Affordable Care Act subsidies at the end of 2025, Cardinal Health has not yet observed a decline in demand, indicating the company's resilience in the face of potential patient cost increases.
- Trends in Healthcare Demand: With the aging American population, healthcare demand continues to rise, and Cardinal Health aligns with government goals to enhance access, affordability, and innovation, aiming to optimize the overall efficiency of the healthcare ecosystem.
- Tariff Pressure Management: In response to tariff pressures, Cardinal Health has adopted a transparent pricing strategy within its medical products business, where, despite efforts to enhance operational efficiency, the company has raised prices on key products to offset rising costs, reflecting market realities.
- Market Adaptability: Despite facing policy and market challenges, Cardinal Health is committed to maintaining accessibility and innovation in healthcare services through collaboration with the government, ensuring competitiveness in a rapidly changing healthcare environment.
- Healthcare Sector Performance: In Thursday's trading, healthcare stocks emerged as the best-performing sector, rising by 0.2%, with McKesson Corp (MCK) leading the charge with a 16.6% gain, indicating strong market demand that could attract more investor interest in the sector.
- Cardinal Health's Gains: Cardinal Health, Inc. (CAH) also performed well, with a 9.0% increase, suggesting a solid position in the healthcare supply chain that may further enhance its market share and investor confidence.
- ETF Trends: Despite the overall positive performance in healthcare, the Health Care Select Sector SPDR ETF (XLV) fell by 0.5%, indicating a preference for individual stocks over ETFs, which may lead to a shift in capital towards more promising equities.
- Utilities Sector Stability: The utilities sector showed relative stability, with CMS Energy Corp (CMS) up 2.4% and PPL Corp (PPL) up 1.4%, reflecting investor preference for stable returns, which may attract more capital into this sector in the future.
- McKesson Earnings Beat: McKesson's fiscal third-quarter earnings per share exceeded Wall Street's highest estimates, and the adjusted full-year EPS guidance was raised above analyst consensus, leading to a 16% stock price increase, indicating strong performance in the medical supply sector.
- Bob's Discount Furniture IPO: Bob's Discount Furniture debuted on the New York Stock Exchange with shares priced at $17, recently rising 10%, marking a successful entry into the public market and laying the groundwork for future growth.
- Fluence Energy Earnings Miss: Fluence Energy reported first-quarter revenue of $475.2 million, falling short of the $481.2 million consensus, with a per-share loss of 34 cents missing the 21-cent loss estimate, resulting in a 31% stock price drop, reflecting market concerns over its profitability.
- Cardinal Health Guidance Raised: Cardinal Health reported quarterly adjusted earnings of $2.63 per share, exceeding the $2.36 consensus, with revenue of $65.63 billion surpassing the $64.14 billion estimate, leading to an 8% stock price increase, showcasing strong growth potential in the healthcare services sector.

- Fiscal-Year Outlook Increase: Cardinal Health has raised its fiscal-year outlook for the second time in less than a month.
- Positive Financial Performance: The company’s recent adjustments indicate strong financial performance and confidence in future growth.

- Fiscal-Year Outlook Increase: Cardinal Health has raised its fiscal-year outlook for the second time in less than a month.
- Positive Financial Performance: The company’s recent adjustments indicate strong financial performance and confidence in future growth.
- Strong Earnings Report: Cardinal Health reported a non-GAAP diluted EPS of $2.63 for Q2 FY2026, a 36% increase from $1.93 in the same period last year, indicating a significant improvement in profitability.
- Robust Revenue Growth: The pharmaceutical and specialty solutions segment saw a 19% year-over-year revenue growth, reaching $60.7 billion, reflecting strong market demand and the company's competitive position in the industry.
- Upgraded Full-Year Guidance: The company raised its FY2026 non-GAAP diluted EPS guidance to $10.15 to $10.35, up from the previous range of $9.65 to $9.85, demonstrating confidence in future performance.
- Cash Flow Status: As of the end of FY2025, Cardinal Health had approximately $2.8 billion in cash and equivalents, down from $3.9 billion on June 30, 2025, highlighting the need for careful liquidity management.









